Cette page a été traduite automatiquement et l'exactitude de la traduction n'est pas garantie. Veuillez vous référer au version anglaise pour un texte source.

Onvansertib en association avec l'irinotécan nanoliposomal, la leucovorine et le fluorouracile pour le traitement de deuxième intention des participants atteints d'un adénocarcinome canalaire pancréatique métastatique

3 novembre 2026 mis à jour par: Cardiff Oncology

Une étude de phase 2 sur l'onvansertib en association avec l'irinotécan nanoliposomal, la leucovorine et le fluorouracile pour le traitement de deuxième intention des patients atteints d'un adénocarcinome canalaire pancréatique métastatique

The main objective of this trial is to assess the efficacy of onvansertib in combination with nanoliposomal irinotecan (nal-IRI), leucovorin, and fluorouracil (5-FU) for treatment of participants with histologically confirmed metastatic PDAC.

Aperçu de l'étude

Type d'étude

Interventionnel

Inscription (Réel)

41

Phase

  • Phase 2

Contacts et emplacements

Cette section fournit les coordonnées de ceux qui mènent l'étude et des informations sur le lieu où cette étude est menée.

Lieux d'étude

    • Arizona
      • Phoenix, Arizona, États-Unis, 85054
        • Mayo Clinic Phoenix
    • Florida
      • Jacksonville, Florida, États-Unis, 32224
        • Mayo Clinic Jacksonville
    • Kansas
      • Westwood, Kansas, États-Unis, 66205
        • University of Kansas Medical Center
    • Minnesota
      • Rochester, Minnesota, États-Unis, 55905
        • Mayo Clinic Rochester
    • Nebraska
      • Omaha, Nebraska, États-Unis, 68198
        • University of Nebraska Medical Center
    • Virginia
      • Fairfax, Virginia, États-Unis, 22031
        • Inova Schar Cancer Institute

Critères de participation

Les chercheurs recherchent des personnes qui correspondent à une certaine description, appelée critères d'éligibilité. Certains exemples de ces critères sont l'état de santé général d'une personne ou des traitements antérieurs.

Critère d'éligibilité

Âges éligibles pour étudier

18 ans et plus (Adulte, Adulte plus âgé)

Accepte les volontaires sains

Non

Sexes éligibles pour l'étude

Tout

La description

Inclusion Criteria:

  • Histologically or cytologically confirmed metastatic PDAC
  • Has received 1 prior gemcitabine-based chemotherapy as first line therapy for metastatic disease. Progression after completion of neoadjuvant or adjuvant therapy of < 6 months in duration is considered 1 line of therapy for metastatic disease
  • Has measurable disease according to Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1), defined as at least 1 lesion that can be accurately measured in at least 1 dimension (longest diameter to be recorded) as > 20 mm with conventional techniques or as > 10 mm with spiral computed tomography (CT) scan
  • Eastern Cooperative Oncology Group (ECOG) Performance Status 0-1
  • Must be willing and able to undergo a tissue biopsy at screening; participants who, in the opinion of the investigator, do not have tissue that is accessible for biopsy are excepted from this criterion
  • Women of childbearing potential: (defined as not post-menopausal for 12 months or no previous surgical sterilization) and fertile men must agree to use adequate contraception for the duration of study participation and for 4 months after the last dose of nal-IRI. Male subjects must agree to refrain from sperm donation during the study and for 4 months after the last dose of nal-IRI
  • Ability to understand and the willingness to sign a written informed consent document. Signed informed consent form must be obtained prior to initiation of study evaluations and/or activities
  • International Normalized Ratio (INR) < 1.5 unless on warfarin
  • Participants with prior malignancy and who were treated with no evidence of active disease more than 2 years from initial diagnosis are eligible
  • Age ≥ 18 years
  • Participants must have adequate organ and bone marrow function

Exclusion Criteria:

  • Prior treatment with irinotecan, nal-IRI, or investigational PLK1 inhibitor
  • Uncontrolled intercurrent illness including symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, and myocardial infarction within 3 months of initiation of therapy
  • History of interstitial pneumonitis or interstitial lung disease
  • Participants with microsatellite instability-high (MSI-H) tumors with no prior immune checkpoint inhibitor exposure
  • Pregnancy or lactation
  • Participant has active and uncontrolled bacterial, viral, or fungal infection(s) requiring systemic therapy
  • QT interval with Fridericia's correction (QTcF) > 470 milliseconds. The QTcF should be calculated as the arithmetic mean of the QTcF on triplicate electrocardiograms (ECGs). In the case of potentially correctible causes of QT prolongation, (eg, medications, hypokalemia), the triplicate ECG may be repeated once during Screening and that result may be used to determine eligibility
  • Planned concomitant use of medications known to prolong the QT/QTc interval
  • Participant has undergone major surgical resection within 4 weeks prior to enrollment
  • Participant received radiotherapy, surgery, chemotherapy, or an investigational therapy within 2 weeks prior to study entry
  • Participant has serious medical risk factors involving any of the major organ systems such that the investigator considers it unsafe for the participant to receive an experimental research drugs
  • Serious psychiatric or medical conditions that could interfere with treatment
  • Major bleeding in the last 4 weeks
  • More than 1 prior chemotherapy regimen administered in the metastatic setting
  • Unable or unwilling to swallow oral medication
  • Use of strong CYP3A4 or UGT1A1 inhibitors or strong CYP3A4 inducers. Participants currently receiving these agents who are able to switch to alternate therapy are not excluded. Inhibitors should be stopped at least one week prior to the first dose of protocol therapy and inducers should be stopped at least two weeks prior to initiation of protocol therapy.

Plan d'étude

Cette section fournit des détails sur le plan d'étude, y compris la façon dont l'étude est conçue et ce que l'étude mesure.

Comment l'étude est-elle conçue ?

Détails de conception

  • Objectif principal: Traitement
  • Répartition: Non randomisé
  • Modèle interventionnel: Affectation séquentielle
  • Masquage: Aucun (étiquette ouverte)

Armes et Interventions

Groupe de participants / Bras
Intervention / Traitement
Expérimental: Safety Lead-in: Onvansertib + nal-IRI + leucovorin + 5-FU

The first 3 participants will be administered onvansertib orally once a day at a dosing schedule of 12 mg/m^2 on Day 1 to Day 10 for two cycles, where each cycle is 2 weeks. Depending on the number of dose limiting toxicities (DLTs) experienced in the first 3 participants, additional participants may receive different dosing schedules, determining the dosing schedule to be used in the treatment period. Onvansertib will be administered in combination with 70 mg/m^2 nanoliposomal irinotecan (nal-IRI), 400 mg/m^2 leucovorin and 2400 mg/m^2 fluorouracil (5-FU).

Intravenous infusion

Oral capsule

Autres noms:
  • PCM-075

Intravenous infusion

Autres noms:
  • Onivyde
  • Nal-IRI

Intravenous infusion

Autres noms:
  • 5-FU
Expérimental: Treatment Period: Onvansertib + nal-IRI + leucovorin + 5-FU

Participants will be administered onvansertib at the dosing schedule selected based on the results of the safety lead-in, in cycles of 2 weeks. Onvansertib will be administered in combination with 70 mg/m^2 nanoliposomal irinotecan (nal-IRI), 400 mg/m^2 leucovorin and 2400 mg/m^2 fluorouracil (5-FU).

Intravenous infusion

Oral capsule

Autres noms:
  • PCM-075

Intravenous infusion

Autres noms:
  • Onivyde
  • Nal-IRI

Intravenous infusion

Autres noms:
  • 5-FU

Que mesure l'étude ?

Principaux critères de jugement

Mesure des résultats
Description de la mesure
Délai
Overall Response Rate (ORR) Per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1
Délai: Up to approximately 91 weeks

ORR was defined as the percentage of participants who achieved a best overall response of confirmed complete reponse (CR) or partial response (PR) determined by the Investigator per RECIST v1.1.

According to RECIST 1.1, a CR is the disappearance of all target lesions, with non-target lesions non-existent and no new lesions and a PR is a decrease of at least 30% in the sum of the diameters of target lesions, as long as there are no new lesions and non-target lesions have not worsened.

Two-sided 95% confidence interval (CI) was calculated using the exact binomial Clopper-Pearson method.

Up to approximately 91 weeks

Mesures de résultats secondaires

Mesure des résultats
Description de la mesure
Délai
Overall Survival (OS)
Délai: Up to approximately 21 months

OS was calculated as: OS = (date of death - date of first dose of study treatments + 1)/ 30.4375.

95% CI was estimated using the Kaplan-Meier method.

Up to approximately 21 months
Duration of Response (DOR)
Délai: Up to approximately 91 weeks

DOR was calculated as: DOR = (date of recurrence or progression of disease or all-cause death - date of first confirmed CR or PR + 1)/30.4375. Only participants who had a confirmed CR or PR were included in the analysis, and the percentage was based on the number of participants who had such a response.

95% CI was estimated using the Kaplan-Meier method.

Up to approximately 91 weeks
Number of Participants Who Experienced Treatment-emergent Adverse Events (TEAEs)
Délai: Up to approximately 91 weeks

TEAEs were defined as AEs that first occurred or worsened in severity on or after the first administration of trial treatments and up to 30 days after the last administration of trial treatments.

Up to approximately 91 weeks
Disease Control Rate (DCR)
Délai: Up to approximately 91 weeks

DCR was defined as the percentage of participants who achieved a best overall response of confirmed CR or PR, or stable disease (SD) determined by the Investigator per RECIST v1.1.

Two-sided 95% CI was calculated using the exact binomial Clopper-Pearson method.

Up to approximately 91 weeks

Collaborateurs et enquêteurs

C'est ici que vous trouverez les personnes et les organisations impliquées dans cette étude.

Parrainer

Dates d'enregistrement des études

Ces dates suivent la progression des dossiers d'étude et des soumissions de résultats sommaires à ClinicalTrials.gov. Les dossiers d'étude et les résultats rapportés sont examinés par la Bibliothèque nationale de médecine (NLM) pour s'assurer qu'ils répondent à des normes de contrôle de qualité spécifiques avant d'être publiés sur le site Web public.

Dates principales de l'étude

Début de l'étude (Réel)

25 mai 2021

Achèvement primaire (Réel)

24 décembre 2024

Achèvement de l'étude (Réel)

24 décembre 2024

Dates d'inscription aux études

Première soumission

9 février 2021

Première soumission répondant aux critères de contrôle qualité

9 février 2021

Première publication (Réel)

12 février 2021

Mises à jour des dossiers d'étude

Dernière mise à jour publiée (Réel)

4 novembre 2026

Dernière mise à jour soumise répondant aux critères de contrôle qualité

3 novembre 2026

Dernière vérification

1 juin 2026

Plus d'information

Termes liés à cette étude

Plan pour les données individuelles des participants (IPD)

Prévoyez-vous de partager les données individuelles des participants (DPI) ?

NON

Informations sur les médicaments et les dispositifs, documents d'étude

Étudie un produit pharmaceutique réglementé par la FDA américaine

Oui

Étudie un produit d'appareil réglementé par la FDA américaine

Non

Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .

S'abonner